Citadel Advisors’s ANI Pharmaceuticals ANIP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.85M | Buy |
115,082
+94,667
| +464% | +$7.39M | ﹤0.01% | 3426 |
|
|
2025
Q4 | $1.61M | Sell |
20,415
-559,670
| -96% | -$48.5M | ﹤0.01% | 6356 |
|
|
2025
Q3 | $53.1M | Buy |
580,085
+10,455
| +2% | +$853K | 0.01% | 1320 |
|
|
2025
Q2 | $37.2M | Sell |
569,630
-153,699
| -21% | -$10M | 0.01% | 1485 |
|
|
2025
Q1 | $48.4M | Buy |
723,329
+131,735
| +22% | +$7.87M | 0.01% | 1174 |
|
|
2024
Q4 | $32.7M | Buy |
591,594
+61,717
| +12% | +$3.54M | 0.01% | 1661 |
|
|
2024
Q3 | $31.6M | Buy |
529,877
+161,538
| +44% | +$9.85M | 0.01% | 1630 |
|
|
2024
Q2 | $23.5M | Buy |
368,339
+249,573
| +210% | +$16.2M | ﹤0.01% | 1835 |
|
|
2024
Q1 | $8.21M | Sell |
118,766
-55,230
| -32% | -$3.33M | ﹤0.01% | 3189 |
|
|
2023
Q4 | $9.59M | Buy |
173,996
+125,166
| +256% | +$6.89M | ﹤0.01% | 2905 |
|
|
2023
Q3 | $2.84M | Buy |
48,830
+2,547
| +6% | +$147K | ﹤0.01% | 4579 |
|
|
2023
Q2 | $2.49M | Buy |
46,283
+45,915
| +12,477% | +$2.04M | ﹤0.01% | 4774 |
|
|
2023
Q1 | $14.6K | Buy |
368
+45
| +14% | +$1.9K | ﹤0.01% | 13295 |
|
|
2022
Q4 | $13K | Sell |
323
-8,528
| -96% | -$320K | ﹤0.01% | 13474 |
|
|
2022
Q3 | $284K | Sell |
8,851
-63,365
| -88% | -$2.17M | ﹤0.01% | 9701 |
|
|
2022
Q2 | $2.14M | Buy |
72,216
+64,228
| +804% | +$1.85M | ﹤0.01% | 5404 |
|
|
2022
Q1 | $224K | Sell |
7,988
-15,138
| -65% | -$564K | ﹤0.01% | 11251 |
|
|
2021
Q4 | $1.07M | Sell |
23,126
-9,460
| -29% | -$406K | ﹤0.01% | 7793 |
|
|
2021
Q3 | $1.07M | Sell |
32,586
-5,423
| -14% | -$169K | ﹤0.01% | 7977 |
|
|
2021
Q2 | $1.33M | Sell |
38,009
-11,300
| -23% | -$384K | ﹤0.01% | 7595 |
|
|
2021
Q1 | $1.78M | Sell |
49,309
-18,528
| -27% | -$580K | ﹤0.01% | 6683 |
|
|
2020
Q4 | $1.97M | Buy |
67,837
+35,753
| +111% | +$1.02M | ﹤0.01% | 5383 |
|
|
2020
Q3 | $905K | Buy |
+32,084
| New | +$955K | ﹤0.01% | 6214 |
|
|
2020
Q2 | – | Sell |
-8,956
| Closed | -$365K | – | 9721 |
|
|
2020
Q1 | $365K | Buy |
8,956
+491
| +6% | +$26.1K | ﹤0.01% | 6980 |
|
|
2019
Q4 | $522K | Buy |
+8,465
| New | +$561K | ﹤0.01% | 6742 |
|
|
2019
Q3 | – | Sell |
-6,520
| Closed | -$488K | – | 9119 |
|
|
2019
Q2 | $536K | Sell |
6,520
-5,225
| -44% | -$372K | ﹤0.01% | 6720 |
|
|
2019
Q1 | $829K | Sell |
11,745
-2,476
| -17% | -$146K | ﹤0.01% | 5932 |
|
|
2018
Q4 | $640K | Buy |
14,221
+4,634
| +48% | +$243K | ﹤0.01% | 6015 |
|
|
2018
Q3 | $542K | Buy |
+9,587
| New | +$587K | ﹤0.01% | 6566 |
|
|
2018
Q2 | – | Sell |
-4,903
| Closed | -$306K | – | 8771 |
|
|
2018
Q1 | $285K | Sell |
4,903
-1,891
| -28% | -$120K | ﹤0.01% | 6827 |
|
|
2017
Q4 | $438K | Sell |
6,794
-1,484
| -18% | -$92.3K | ﹤0.01% | 5856 |
|
|
2017
Q3 | $435K | Sell |
8,278
-12,438
| -60% | -$593K | ﹤0.01% | 5516 |
|
|
2017
Q2 | $969K | Buy |
20,716
+16,547
| +397% | +$798K | ﹤0.01% | 4123 |
|
|
2017
Q1 | $206K | Buy |
+4,169
| New | +$234K | ﹤0.01% | 6471 |
|
|
2016
Q4 | – | Sell |
-14,113
| Closed | -$863K | – | 7207 |
|
|
2016
Q3 | $936K | Buy |
14,113
+5,171
| +58% | +$323K | ﹤0.01% | 3918 |
|
|
2016
Q2 | $499K | Buy |
+8,942
| New | +$435K | ﹤0.01% | 4488 |
|
|
2015
Q4 | – | Sell |
-25,337
| Closed | -$1.09M | – | 8690 |
|
|
2015
Q3 | $1M | Buy |
+25,337
| New | +$1.44M | ﹤0.01% | 3817 |
|
|
2015
Q2 | – | Sell |
-5,457
| Closed | -$325K | – | 8696 |
|
|
2015
Q1 | $341K | Sell |
5,457
-704
| -11% | -$42.8K | ﹤0.01% | 5468 |
|
|
2014
Q4 | $348K | Sell |
6,161
-4,716
| -43% | -$208K | ﹤0.01% | 5217 |
|
|
2014
Q3 | $307K | Sell |
10,877
-6,500
| -37% | -$195K | ﹤0.01% | 5240 |
|
|
2014
Q2 | $599K | Buy |
17,377
+1,677
| +11% | +$52.6K | ﹤0.01% | 4150 |
|
|
2014
Q1 | $492K | Buy |
+15,700
| New | +$417K | ﹤0.01% | 4362 |
|
|
2013
Q3 | – | Sell |
-2,244
| Closed | -$13K | – | 6699 |
|
|
2013
Q2 | $13K | Buy |
+2,244
| New | +$15.7K | ﹤0.01% | 6169 |
|
Other funds holding ANIP
VCM
SCM
TCM
GAM
DTC
Citadel Advisors's ANIP Position: Q1 2026 in Review
Citadel Advisors increased its ANI Pharmaceuticals (ANIP) stake by 464% in Q1 2026, buying an estimated $7.39M and bringing the position to 115,082 shares worth $8.85M. The position accounts for ﹤0.01% of the portfolio, ranked #3426.
Citadel Advisors first reported a position in ANIP in Q2 2013 and has held it in 43 quarters since. The position peaked at $53.1M in Q3 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.
- Citadel Advisors held 115,082 shares of ANI Pharmaceuticals worth $8.85M as of Q1 2026.
- Citadel Advisors bought 94,667 ANI Pharmaceuticals shares in Q1 2026, an estimated $7.39M.
- ANI Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3426 holding.
- Citadel Advisors first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
- Citadel Advisors's ANI Pharmaceuticals position peaked at $53.1M in Q3 2025.
- 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.